Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTX-MC138 in advanced solid tumors
NCT06260774Phase 2Active, not recruiting
- Sponsor
- TransCode Therapeutics, Inc.
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of TTX-MC138 in solid tumor (advanced stage) (3 arms), sponsored by TransCode Therapeutics, Inc. Primary endpoints: Adverse Events and Overall Response Rate. Started Sep 2024; status: active, not recruiting.
02
Drugs
TTX-MC138
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06260774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260774.